Emily Murrell
About Emily Murrell
Emily Murrell is a scientist at Bristol Myers Squibb in Princeton, New Jersey, with expertise in the synthesis of PET and SPECT radioligands for oncology and neurology applications.
Current Position at Bristol Myers Squibb
Emily Murrell holds the position of Scientist at Bristol Myers Squibb, based in Princeton, New Jersey, United States. In this role, she leverages her extensive knowledge in radiochemistry and her expertise in synthesizing PET and SPECT radioligands to collaborate with medicinal chemists and imaging scientists. Her work primarily serves oncology and neurology applications, contributing to the advancement of radiopharmaceuticals and imaging techniques.
Previous Experience at CAMH
From 2019 to 2021, Emily Murrell worked as a Postdoctoral Research Fellow at the Centre for Addiction and Mental Health (CAMH) in Toronto, Ontario, Canada. During her two-year tenure, she was involved in pioneering research projects in the field of radiochemistry. Her work at CAMH was instrumental in advancing the understanding and application of radioligands in neurological research.
Teaching and Research at Western University
Emily Murrell served as a Graduate Teaching Assistant at Western University from 2014 to 2019. Over these five years, she was responsible for teaching and mentoring undergraduate students while pursuing her PhD in Organic Chemistry and Molecular Imaging. Her academic work focused on the synthesis and application of radiochemicals, significantly contributing to her field.
Educational Background
Emily Murrell achieved her PhD in Organic Chemistry and Molecular Imaging from Western University, where she studied from 2014 to 2019. Prior to that, she completed her Honours Bachelor of Science (BSc) in Chemistry at Dalhousie University, studying from 2009 to 2013. Her education provided her with a solid foundation in radiochemistry and its applications in medical imaging.
Expertise in Radiopharmaceuticals
Emily Murrell has a strong background in the synthesis of PET and SPECT radioligands, particularly for oncology and neurology applications. She specializes in working with radiochemicals such as F-18, C-11, and Tc-99m. Her interdisciplinary experience spans both academic research and industrial applications, and she has a robust publication and presentation record in the radiopharmaceutical field.